Make sterile connections faster, easier and safer with genderless connectors - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Make sterile connections faster, easier and safer with genderless connectors

Genderless AseptiQuik® G sterile connectors from CPC simplify single-use systems design and process integration. Our innovative design eliminates separate male and female components to substantially reduce complexity and support modular system design. Because the connectors are interchangeable—any single-use G series connector mates with any other G series connector—systems are more flexible and minimize supply chain complexity.

G series connectors are available in a full range of interchangeable 6.4 mm to 19.0 mm (1/4” to 3/4”) flow solutions, in both gamma and high-temperature versions. Terminations include 6.4 mm to 19.0 mm hose barb and 19.0 mm mini-sanitary.

The G series is part of the AseptiQuik family which offers the broadest range of single-use sterile connectors in the industry with flow configurations from 3.2 mm to 25.4 mm (1/8” to 1”). AseptiQuik connectors provide ease-of-use, robust construction and reliable performance for transferring valuable media. AseptiQuik’s are ideal for single-bag and tubing assemblies,cell banking, bioreactors, mixers,
sampling, formulation and filling applications.

See how the G series works AseptiQuik G video

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here